Exelixis, Inc. (NASDAQ:EXEL) EVP Sells $426,800.00 in Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $42.68, for a total value of $426,800.00. Following the completion of the transaction, the executive vice president now directly owns 491,164 shares in the company, valued at $20,962,879.52. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Exelixis Stock Performance

Shares of Exelixis stock opened at $45.40 on Monday. The firm has a fifty day moving average of $37.23 and a two-hundred day moving average of $35.84. The stock has a market capitalization of $12.51 billion, a price-to-earnings ratio of 25.65, a PEG ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $48.85.

Institutional Trading of Exelixis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Coppell Advisory Solutions LLC acquired a new position in shares of Exelixis in the 4th quarter valued at $25,000. Hemington Wealth Management boosted its stake in shares of Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock worth $28,000 after buying an additional 522 shares during the last quarter. Colonial Trust Co SC boosted its stake in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock worth $30,000 after buying an additional 765 shares during the last quarter. USA Financial Formulas acquired a new stake in Exelixis in the 4th quarter valued at about $32,000. Finally, Principal Securities Inc. lifted its stake in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 373 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EXEL. UBS Group reissued an “underperform” rating on shares of Exelixis in a report on Thursday, April 17th. Stephens restated an “equal weight” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Citigroup boosted their price objective on shares of Exelixis from $45.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price objective on shares of Exelixis in a research report on Wednesday, May 14th. Finally, Piper Sandler boosted their price objective on shares of Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Exelixis has an average rating of “Moderate Buy” and an average target price of $38.76.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.